Comparative study of anlotinib and cabozantinib

Anlotinib and cabozantinib are currently widely used targeted drugs in clinical practice for the treatment of various types of cancer.

Anlotinib is mainly used to treat non-small cell lung cancer, especially patients who have progressed or relapsed after chemotherapy. In addition, it also has a certain effect on alveolar soft tissue sarcoma, clear cell sarcoma, etc. Cabozantinib is more widely used in a variety of cancers, including non-small cell lung cancer, liver cancer, kidney cancer and thyroid cancer. In the treatment of EGFR mutant lung cancer, cabozantinib can significantly prolong the survival of patients.

Both are tyrosine kinase inhibitors that prevent the growth and spread of cancer cells by inhibiting key molecules in tumor development. Anlotinib is a multi-target receptor tyrosine kinase inhibitor that can effectively inhibit a variety of tumor cell lines. Cabozantinib exerts anti-tumor effects by inhibiting the EGFR signaling pathway and vascular endothelial growth factor receptor (VEGFR).

Common side effects of anlotinib include hypertension, fatigue, hand-foot skin reaction, etc., while cabozantinib may cause adverse reactions such as diarrhea, loss of appetite, fatigue, nausea, vomiting, and hypertension. When using these two drugs, the patient's response needs to be closely monitored and dosage adjustments or discontinuation made as appropriate.

In terms of specific selection, the decision on which drug to use should be based on the patient's specific situation, cancer type, and doctor's recommendations. Anlotinib has shown efficacy in certain types of sarcoma and non-small cell lung cancer, while cabozantinib has shown efficacy in a variety of cancers due to its broad target range.